Although a variety of trial and registry data are available to complement individual clinician experience and patient testimonials, there is currently no comprehensive systematic review of CF LVADs that attempts to summarize and organize available information into a practical format. Existing guidelines and standard consent forms do not provide such summary data with any degree of detail. 3 This absence of accurate and easily accessible information from which to anchor riskbenefit communication leads to a potentially nonstandardized and variable informed consent and decision-making process around LVADs that may be incomplete, confusing, or biased. 4, 5 Therefore, we aimed to summarize the current evidence on risks and benefits of CF LVADs. Our objectives were to (1) capture contemporary clinical data on outcomes for patients offered CF LVADs; (2) describe the nature and quality of this evidence; (3) organize the data in a way that conveys the full range of expected outcomes for CF LVADs, with direct comparisons to outcomes without implantation; and (4) identify critical gaps in the scientific data that should be a priority of future research. Our primary goal was to provide a practical document that could guide a more standardized informed consent process and future development of decision aids for CF LVADs.
L eft ventricular assist devices (LVADs) are becoming an increasingly viable treatment option for patients with endstage heart failure. Newer generation continuous-flow (CF) LVADs have taken the place of the first-generation pulsatileflow LVADs because of their smaller size and greater durability. Ideal informed consent and shared decision making for LVADs should be grounded in a thorough review of expected risks and benefits. 1 This process should compare and contrast LVAD therapy to alternative approaches and include not only estimates of survival but also major adverse events, healthrelated quality of life (HRQoL), symptom burden, functional limitations, and obligations for caregivers. 2 
Study Selection
Eligible articles were presented in English and provided primary data about outcomes of CF LVADs. Two study team members independently reviewed all titles and abstracts for initial selection for inclusion (A.V.A. and L.A.A.). When the title and abstract provided insufficient information to determine study relevance, a full-text copy of the article was retrieved and reviewed. For final selection, full-text copies of all initially selected articles were examined for study eligibility.
The following exclusion criteria were applied: studies that included <50 patients with CF devices, reviews or editorials on CF LVADs, studies that were nonhuman or focused on imagine with CF LVADs, studies that focused on surgical techniques, studies restricted to pediatric populations, studies that reported outcomes on temporary devices or partial support, studies with a transplant focus, studies that did not separate data based on CF versus pulsatile-flow device, studies reporting on other devices such as intra-aortic balloon pumps, studies reporting data on risk modeling and CF LVADs, studies that were updated by newer publications, and subanalyses of previously reported results.
In addition, for serial publications updating longitudinal registry findings, we included only the most recent publication that addressed a specific outcome. We also excluded articles focused on risk modeling for which the overall outcome frequency for the same population was published elsewhere. Exceptions were made for evidence sources that were frequently referenced by more contemporary publications. Figure 1 summarizes the evidence search and selection. For each article excluded, a single most obvious exclusion criterion was chosen, even though many articles met multiple exclusion criteria.
Data Extraction and Quality Assessment
From each study, 2 independent reviewers (K.H.M. and J.S.T.) extracted total patients, total CF patients, type of device (CF, pulsatile-flow), specific model of device (eg, Thoratec HeartMate II [HMII], HeartWare HeartWare ventricular assist device [HVAD]), duration of follow-up or defined time at risk, population characteristics (BTT, DT), and outcome measures (survival, functional status, HRQoL, bleeding, neurological events, infection, device malfunction, right heart failure, arrhythmia, aortic insufficiency, renal failure, and rehospitalizaion). These outcomes were chosen by a group of clinicians, patients, and families as most important to CF LVAD therapy. Definitions for each outcome are included in Figure II in the Data Supplement. A third reviewer (C.K.M.) independently reviewed and confirmed all data abstracted. Disagreements were resolved through discussion by the entire study team. We aimed to include all relevant studies that reported outcomes for CF devices that met our stated inclusion and exclusion criteria. Assessment of quality was based on study design. The studies were categorized in the order of rigor: (1) industry-funded trials and related prospective registries, which included all controlled trials related to CF devices; (2) multicenter registries; and (3) single-center reports and case series.
Data Synthesis
Data were summarized in tabular form. The resulting tables were organized according to the prospectively identified key patient-centered outcome domains of interest: survival, HRQoL and functional status, and adverse events. Where necessary, we manually calculated cumulative numbers when data were only reported separately for subgroups. When relevant data were only presented in graphic form, quantitative estimates were extracted and reported. Narrative syntheses of data were added to supplement the tables, incorporate nuanced information about data generation and quality, and provide a holistic summary. To create a clinically useful synopsis that may help facilitate communication with patients and families, we performed a crude analytic summary of the existing data. After reviewing the literature for all reported outcomes, we solicited feedback from physicians, physician assistants, nurse practitioners, nurses, a social worker, patients, and their families about which outcomes should be included in a summary figure. We consolidated hospitalization, bleeding, stroke, and infections, where appropriate, for ease of understanding. Event rates at 1 year were chosen because many studies did not report events for past 1 year. Final outcomes are reported in Figure 2 . We first collated the data from all studies for each outcome and subsequently removed redundant data. We excluded studies that did not report percentage data. Second, we applied the weighted average method based on total study sample and percentage reported. The weighted average method provides a summary treatment effect that more heavily emphasizes data reported from a registry with a large number of patients than a small single-center study. It assumes fixed effects of CF LVAD across studies. The resultant weighted average included all trial, registry, and single-center studies and is reported as an estimated mean for all data. Finally, we applied the weighted average method to calculate the time period reported for each outcome. We were unable to calculate the summary effect sizes because of a variety of barriers, including the clinically diverse nature of the studies and lack of reporting standards.
Results
The electronic search identified 465 titles and abstracts. An additional 2 studies related to pump thrombosis that were currently in press 7, 8 and not identified in the search were added. After inclusion and exclusion criteria were applied, a total of 52 full-text articles were included and reviewed ( Table I in the Data Supplement). The majority of studies were nonrandomized, observational, small power, or single center. The studies included 10 industry-funded trials, 10 multicenter reports (many were different analyses of the same ongoing registry), and the remainder single-center observational experiences. Several multicenter registry publications that highlighted particular outcomes of interest were subanalyses or post hoc analyses of existing databases. Similarly, ongoing registries tended to be used for serial publications on individual outcomes.
On the basis of data extracted, we identified 10 relevant patient-centered outcomes for which data were reported: survival, HRQoL, functional status, bleeding, neurological events, infection, device malfunction, right heart failure, arrhythmias, and rehospitalizations. All single-center studies and those with <100 patients with CF LVAD are summarized in Tables II to IV in the Data Supplement. A summary of simplified 1-year outcomes using weighted averages, including all data, is provided Figure 2 . A pictograph was developed according to accepted patient communication methods, 9 and feedback from clinicians, nurses, and patients was provided on content and readability.
Survival

(6 Industry-Funded Trials and Related Registries 10-14 ; 6 Multicenter Registries 7,15-19 ; 9 Single-Center Reports or Case Series. See Data Supplement for all single-center studies and those with <100 patients with CF LVAD)
Survival is the outcome of dominant importance to the majority of patients. 20 Extending life is a primary goal of LVADs, and therefore communicating statistics around mortality is critical. Although survival is an objective measure, characterizing long-term survival after LVAD implantation is complicated by several factors, including finite study time periods, patient loss to follow-up, and censoring of patients at the time of transplantation. Even in the DT population, a significant minority of patients will later become transplant eligible (≈10% in DT trial populations). 12 Therefore, estimated actuarial survival is most often reported.
Most studies reported survival rates at times postimplantation ranging from 1 to 24 months, with less data beyond 2 years ( Table 1 ). The pivotal HMII DT Trial showed estimated actuarial survival at 2 years of 58%. 12 The Interagency Registry for Mechanically Assisted Circulatory Support (INTERMACS) Fifth Annual Report showed 1-, 12-, 24-, 36-, and 48-month survival at 95%, 80%, 70%, 59%, and 47%, respectively. 19 These values represent some of the most recent data and some of the highest rates of survival for patients with CF LVAD. The ADVANCE: HVAD BTT Trial Continued Access Protocol also illustrated improved survival 6 months and 1 year after device implantation when compared with trials performed in earlier years. 14 However, to what extent progressive improvements in survival represent true improvements in the use of the device versus patient selection into less sick populations is unclear.
HRQoL and Functional Status
(6 Industry-Funded Trials and Related Registries 10-14,21 ; 1
Multicenter Registry) 19 One of the main goals of LVAD implantation is to improve the HRQoL and functional capacity for patients with symptomatic heart failure. Improvements in New York Heart Association functional class are common after LVAD implantation. Approximately 80% of patients improved from New York Heart Association class IIIB or IV at baseline to New York Heart Association class I or II symptoms after LVAD in the HMII BTT and DT trials. 10, 12 In addition, instruments commonly used to assess HRQoL in patients with heart failure that are often prospectively collected in LVAD studies include heart failure disease-specific measures, such as the Minnesota Living with Heart Failure Questionnaire, 22 the Kansas City Cardiomyopathy Questionnaire, 23 and general measures such as the European Quality of Life-5 Dimensions. 24 In addition to subscales of HRQoL questionnaires, functional status is most commonly assessed through 6-minute walk distance. Among patients who survive with LVADs, HRQoL measures improve markedly from baseline ( Table 2 ). The collective HMII studies demonstrated significant improvements in Minnesota Living with Heart Failure Questionnaire and Kansas City Cardiomyopathy Questionnaire scores, as well as 6-minute walk distance from before surgery to all time points assessed after device implantation. [10] [11] [12] 21 In addition, the most recent INTERMACS Annual Report demonstrated overall improvements in the European Quality of Life-5 Dimensions visual analog scale, and fewer patients identified themselves as having extreme problems with self-care and usual activities. 19 It should be noted that HRQoL and functional status data have typically censored patients at the time of death, which can progressively enrich for a healthier population. In addition, missing data for HRQoL and functional status measures are more common than for an outcome like survival, with 13% to 38% of patients unable to complete health status or functional assessments at a given time point. 10, 12 However, this failure to complete health status assessments can itself be informative, with worse outcomes commonly seen in these patients. 10, 12 Finally, the HRQoL measures developed in patients with chronic heart failure may not perform as intended when applied to the LVAD population, given that many heart failure-related symptoms are traded for other unique symptoms and burdens. 25
Common Adverse Events
Although LVADs offer patients the potential for improved survival, HRQoL, and functional status, there are also several risks associated with LVAD therapy. Some of the most commonly studied and reported major adverse events after LVAD implantation are bleeding, neurological events, and infection.
Definitions for all adverse events are included in Figure II in the Data Supplement.
Bleeding (7 Industry-Funded Trials and Related Registries 10-14 ; 3 Multicenter Registries 16,18,19 ; 14 Single-Center Reports or Case Series. See Data Supplement for all single-center studies and those with <100 patients with CF LVAD)
Bleeding is the most commonly recorded adverse event of CF LVADs, 11, 12, 19 with the majority of patients in all published cohorts experiencing some type of bleeding. When possible, bleeding rates are reported by <30 days (early) and >30 days (late) to help differentiate postoperative bleeding from nonsurgical bleeding. A recent study of 139 HMII patients showed the greatest risk of bleeding was within the first 2 weeks postoperatively, and early bleeding was associated with decreased survival. 26 Later gastrointestinal bleeding is reported with rates as high as 13% in the ADVANCE: HVAD BTT Trial Continued Access Protocol. 14 A single-center study of 86 HMII patients reported gastrointestinal bleeding as a frequent source of morbidity for patients but not a factor that significantly impacts survival. 27 19 Similarly, the HMII DT Trial showed rates of ischemic and hemorrhagic stroke as high as 8% and 11%, respectively, in the first 2 years after LVAD placement, with hemorrhagic stroke being the leading cause of death among patients with a CF LVAD. 12 The reported rates of stroke from other reports are variable and likely reflect differences in study follow-up time and the patient population studied; however, the overall annual risk of stroke in CF LVAD patients seems to be substantial.
Infection
(7 Industry-Funded Trials and Related Registries 10-14 ; 4 Multicenter Registries 16,18,19,28 ; 9 Single-Center Reports or Case Series. See Data Supplement for all single-center studies and those with <100 patients with CF LVAD)
Patients are at increased risk of bacterial infections after LVAD implantation, occurring at the driveline, pump pocket, or systemically. Driveline infections in the International HVAD Trial are reported at 18% at 1 year, 29 whereas the HMII BTT trial and trial registry report rates as high as 14% at 6 months. 10, 11 Developing any type of infection is associated with decreased survival and quality of life; 28 in one cohort, 2-year cumulative survival rate was 67% for patients with infections and 81% in those without. 30 A summary of these outcomes, including all trial and registry data with >100 patients with CF LVAD, is provided in Table 3 .
Other Adverse Events
Although bleeding, neurological events, and infection are dominant in adverse events reporting, there are additional complications with CF LVAD therapy that can be equally devastating or have an effect on HRQoL (Table 4 ).
Device Malfunction (7 Industry-Funded Trials and Related Registries 10-14 ; 7 Multicenter Registries 7,8,12,16,18,31,32 ; 4 Single-Center Reports or Case Series. See Data Supplement for all single-center studies and those with <100 patients with CF LVAD)
Device malfunction is a serious adverse event of LVADs because treatment usually requires reoperation and its attendant risks. There are several causes of device malfunction, including thrombus formation with hemolysis, mechanical failure of the impeller, and driveline lead fractures with electric failure. In earlier reports, the highest rate of thrombosis requiring pump exchange was in the International HVAD Trial at 8% at 2 years. 29 However, a recent study from 3 high-volume centers, including 837 HMII patients, shows an increase in the rate of confirmed pump thrombosis at 3 months after implant from 2.2% before March 2011 to 8.4% by January 2013. 32 Analysis of the multicenter INTERMACS registry also confirmed a temporal increase in the rates of HMII thrombosis. 7 Temporal changes in thrombosis rates were not seen in a recent analysis of the HeartWare HVAD. 8 These recent studies illustrate the dynamic potential for rates of adverse events over time, possibly reflecting changes in device technology, patient selection, surgical technique, and postimplantation management.
Right Heart Failure
(8 Industry-Funded Trials and Related Registries 10-14,33 ; 3 Multicenter Registries 16,18,19 ; 7 Single-Center Reports or Case Series. See Data Supplement for all single-center studies and those with <100 patients with CF LVAD)
Right heart failure after LVAD implantation contributes to increased postoperative morbidity and mortality. Outcomes of patients with LVAD are dependent on right heart function because of the necessity of adequate flow through the pulmonary circuit to the left heart. In the HMII DT Trial, 20% of patients received extended inotropic therapy for persistent right heart failure and 4% required placement of a right ventricular assist device. 12 In the ADVANCE: HVAD BTT Trial Continued Access Protocol, 25% of patients became dependent on inotropic therapy and 3% required a right ventricular assist device. 14 The HMII BTT Trial Registry and an analysis of 484 patients enrolled in the HMII BTT Trial reported right heart failure post-LVAD implantation is associated with a marked reduction in rates of survival and longer hospital length of stay. 10, 33 Cardiac Arrhythmias
(6 Industry-Funded Trials and Related Registries 10-14 ; 3 Multicenter Registries 16,18,19 ; 5 Single-Center Reports or Case Series. See Data Supplement for all single-center studies and those with <100 patients with CF LVAD)
Cardiac arrhythmias, both ventricular and supraventricular, can develop after LVAD implantation. A study of 184 HMII devices showed an incidence of ventricular arrhythmias ≤32% after LVAD. 16 Studies have reported conflicting associations of ventricular arrhythmias with survival. A study Figure II of 61 patients reported patients with post-LVAD ventricular arrhythmias had a significantly increased risk of mortality. 34 In contrast, another cohort of 61 patients showed post-LVAD ventricular arrhythmias had no association with survival but did have greater morbidity because patients with post-LVAD ventricular arrhythmias had greater rehospitalizaion rates. 35 In addition, patients with post-LVAD ventricular arrhythmias had higher rates of appropriate (31%) and inappropriate (15%) defibrillator shocks. 35
Adverse events definitions in
Rehospitalizations (4 Industry-Funded Trials and Related Registries 10-12 ; 1 Multicenter Registries 18 ; 7 Single-Center Reports or Case Series. See Data Supplement for all single-center studies and those with <100 patients with CF LVAD)
Recurrent hospital admissions are a common occurrence in patients with LVAD. One trial reported readmission rates as high as 94%, 12 and another reports ≤1.2 admissions per patient year. 29 One study of 71 patients with CF LVAD found that patients are most often readmitted within 6 months of discharge, with gastrointestinal bleeding as the most common cause. 36
Additional Adverse Events
Renal function, neurocognitive function, and aortic insufficiency are additional patient-centered outcomes identified in our electronic search. There are limited studies that report these data; therefore, the outcomes were not included in the tables. Remaining patient-centered outcomes included the following: (1) one study of 107 HMII patients found that 15% required some form of renal replacement therapy post-LVAD implantation 37 ; (2) one study of 96 HMII patients showed no change or improvement in neurocognitive testing post-LVAD implantation 38 ; and (3) one study of 58 HMII patients showed that aortic insufficiency of the native valve progresses with the duration of LVAD support. 39 A summary of these outcomes, including all trial and registry data with >100 patients with CF LVAD, is provided in Table 4 .
Discussion
Permanent mechanical circulatory support in the form of a CF LVAD offers the potential to change the clinical course of severe heart failure fundamentally. Existing evidence shows that, for populations of carefully selected patients, LVADs improve survival, HRQoL, and functional status. Because outcomes in these domains are so dismal without an LVAD, the absolute benefit is marked, with number needed to treat that dwarfs most existing medical therapies. However, despite these dramatic improvements in survival and heart failure symptoms, LVAD therapy remains associated with a significant residual risk of mortality after implantation and the potential for major adverse events in a significant percentage of patients. Thus, for eligible patients, whether to pursue these therapies should involve a careful assessment of the totality of expected risks and benefits over time and how these may relate to a patient's values, goals, and preferences.
Given the complex trade-offs of LVAD therapy, necessary components for shared decision making around CF LVAD must include optimal patient selection, extensive informed consent, and adequate time to review expected risks, benefits, and burdens. To ensure this, LVAD programs are required by the Joint Commission to have a process around education, decision making, and informed consent. Although the ethical mandate surrounding informed consent is clear, 2 achieving true informed consent in this setting is challenging. 1 In addition, providing accurate information to patients in an understandable format to facilitate shared decision making is complicated.
There have been other reviews on LVAD outcomes 40 ; however, there has been no major attempt at systematically reviewing these data according to accepted scientific standards in a patient-focused manner. Several studies have found that graphical presentation of risks and benefits enhances understanding of statistics for patients and families of varying numeracy and literacy skills. 41 The pictograph developed from this systematic review ( Figure 2 ) provides patients, their families, and clinicians an estimate of the full range of CF LVAD outcomes based on weighted averages of all trial, registry, and single-center data published to date. Research has shown that patients differ in their decision-making processes, with some patients viewing survival and quality of life as paramount whereas others weigh risks and burdens more heavily. 20, 42 In response to this, the pictograph provides both benefits and risks; therefore, patients can weigh those outcomes they feel are most important to them. This pictograph could be easily incorporated into existing educational materials and informed consent documents. Although the pictograph does not provide tailored risk estimates and does not show measures of uncertainty for individual patients, we feel it is a significant improvement over existing educational materials. 43 The importance of considering trade-offs for LVAD therapy is particularly salient to the subgroup of patients with a DT indication, who should expect to live the remainder of their life dependent on an LVAD and for whom the reasons making them transplant ineligible will usually persist (advanced age, comorbidity, and frailty). As such, the initial goal of this systematic review was to summarize the risks and benefits of DT LVAD therapy. However, the overall paucity of studies reporting outcomes confined to patients implanted with a DT indication-and the intermixing of DT and BTT patients in some reporting-led to the inclusion of data from BTT populations as well. This allowed for a wider range of evidence; however, the data for BTT patients are not ideal data for informed decision making around DT LVAD. The 2 indications yield different populations and different outcomes for a variety of reasons, including the temporary nature of BTT and the younger age and lower comorbidity of the BTT-eligible population. This limitation is not peculiar to the systematic review, but rather to the state of LVAD research and reporting. Where reported, we have recognized the DT versus BTT indication to help refine interpretation.
Because only 1 device is currently approved in the United States for the DT indication, and only 1 large high-quality trial (HMII DT Trial) was conducted to describe outcomes in this setting, clinicians and patient educational materials for DT often default to the event rates reported from this study. 12 This approach is reasonable given possible threats to scientific validity from lower quality observational data. However, the HMII DT Trial has several limitations that encourage supplementation from other sources. Although a randomized controlled trial, the study compared CF DT LVAD to the older pulsatile-flow LVAD, not to a control group of optimal medical therapy (OMT) patients. In addition, this comparison was unblinded. The trial included only 133 patients in the HMII CF device arm, such that estimates of rare events are potentially unstable. Furthermore, the randomized controlled trial setting, with highly selected patients treated at a limited number of participating centers, may not be particularly generalizable to the usual care setting. Recent reports of higher than expected pump thrombosis rates illustrate these potential concerns. 7, 32 Therefore, systematically reviewing all of the published literature for individual outcomes and then summarizing those estimates in tabular form hopefully offers a more complete picture of the expected range of risks and benefits that clinicians can convey to patients considering LVAD.
In addition to summarizing existing data, the conduct of this systemic review also clarifies deficiencies in the sum of existing data. Data on the survival for DT eligible patients who decline LVAD and continue with OMT are relatively sparse and dated. All studies showed a higher survival rate at every increment of time for patients who received an LVAD when compared with patients who were treated with OMT. [44] [45] [46] Furthermore, the COSI trial showed a dismal 6% survival at 1 year for patients with end-stage heart failure managed with continuous inotropic support. 46 With ranges in 2-year survival of 60% to 70% for CF DT LVAD 12 and 6% to 8% for OMT, 44 the number needed to treat to save one life during a 2-year span is <2 patients. Although survival is significantly improved with LVAD implantation, the absolute rates of death remain relatively high with less than half of patients still alive 4 years after implantation. 19 With improvements in technology, surgical technique, peri-operative care, and patient selection, 47 summary data suggest that for the near-term, patients with CF DT LVAD should expect actuarial survival rates in the 2 years after implantation on the order of 65% to 75%. BTT survival rates are better, with 2-year survival reported as high as 79% to 84%. 14, 29 In a perfect world, studies would randomly compare DT LVADs to OMT. Although randomizing patients to this comparison is essentially unfeasible in most contexts, obtaining additional data on outcomes among OMT populations are possible. The recently launched Medical Arm of INTERMACS (MEDAMACS) 48 and Randomized Evaluation of VAD InterVEntion before Inotropic Therapy (REVIVE-IT) 49 studies should provide additional data on the outcomes of OMT in a group of non-inotrope-dependent advanced heart failure patients. In addition, because of the variation in outcomes by indication, additional studies should aim to separate data collection and outcomes reporting based on BTT versus DT implantation status. Patients who decline DT LVAD may also provide important comparator information.
Furthermore, lack of rigorous standard methodology decreases the use of study information. The nonuniform reporting of event rates limits the ability to pool data across studies. Although events per patient time may be statistically sound, it complicates interpretation for patients with lower numeracy. Similarly, there is no standardized or patient-centered method for accounting for loss to follow-up (eg, death during longitudinal measures of quality of life) or alternative end points (eg, transplantation when calculating survival in DT). In addition, with standardized reporting, summarizing data for longitudinal outcomes reporting would be less problematic. Finally, because of the rapid evolution of mechanical circulatory support, flexible and efficient systems must be developed to help patients and their healthcare providers stay updated on contemporary rates of outcomes. Ultimately, not only is there a desperate need for additional high-quality data but also these data must be collected using standard event definitions, such as the set used by the INTERMACS registry, and reported in units that are mostly clinically meaningful.
Limitations
In addition to the above issues with mixing of BTT and DT, data quality, and nonstandardized reporting, there are several additional limitations that deserve recognition. First, the vast amount of data was difficult to present in a complete and simultaneously understandable format, such that some detail was euthanized for ease of interpretation, both in terms of excluding smaller studies and in simplifying the studies that were included. Second, we included all data on outcomes of CF LVADs without a rigorous exclusion process based on the quality of the study; therefore, interpretation of the data should be guided by the categorized rigor of the study. In-depth review of individual studies may be required by individual healthcare providers ultimately to answer nuanced clinical questions better.
Conclusions
The totality of data for CF LVADs show consistent improvements in survival and quality of life counterbalanced by a range of common complications. Although this summary of outcomes data for CF LVAD should help frame consent, education, and decision making around durable mechanical circulatory support, future action is required to remedy the lack of high-quality data for CF LVAD, particularly in the DT setting. Additional randomized controlled trials with larger patient populations are needed to examine survival, HRQoL, and frequency of complications further. Supplementary trials that report outcomes for a timeline that mirrors the lifespan of DT patients are also necessary. Furthermore, registries for patients on OMT who decline LVAD therapy are critical. An exponential expansion in LVAD use without such information is likely to diminish the overall value that patients and society can derive from this remarkable therapy. responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
